Hormonal replacement therapy in women with Parkinson disease and levodopa-induced dyskinesia: a crossover trial.
Eleven postmenopausal women with Parkinson disease and levodopa-induced peak-dose dyskinesias underwent a double-blind, placebo-controlled, crossover study. The active treatment consisted of estrogen replacement therapy for 12 weeks, followed by medroxyprogesterone acetate for 2 weeks. Estrogen replacement therapy-medroxyprogesterone acetate administration significantly improved peak-dose dyskinesia without worsening motor disability, thus suggesting a possible benefit on dyskinesias in postmenopausal women with Parkinson disease.
Nicoletti
Alessandra
A
Department of Neurosciences, University of Catania, Via Santa Sofia no. 78, 95123 Catania, Italy.
Arabia
Gennarina
G
Pugliese
Pierfrancesco
P
Nicoletti
Giuseppe
G
Torchia
Giusi
G
Condino
Francesca
F
Morgante
Letterio
L
Quattrone
Aldo
A
Zappia
Mario
M
D000368:Aged; D017109:Akathisia, Drug-Induced / Q000188:drug therapy* / Q000209:etiology; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D000978:Antiparkinson Agents / Q000009:adverse effects*; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004967:Estrogens / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D017258:Medroxyprogesterone Acetate / Q000008:administration & dosage*; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D017698:Postmenopause; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018931:Antineoplastic Agents, Hormonal; D000978:Antiparkinson Agents; D004967:Estrogens; D007980:Levodopa; D017258:Medroxyprogesterone Acetate